Poseida Therapeutics (NASDAQ:PSTX – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $20.00 price target on the stock.
Poseida Therapeutics Trading Up 2.2 %
PSTX stock traded up $0.06 during trading on Thursday, hitting $2.83. The company had a trading volume of 833,059 shares, compared to its average volume of 716,364. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average price of $2.97 and a 200-day moving average price of $2.94. Poseida Therapeutics has a 12 month low of $1.54 and a 12 month high of $4.27. The stock has a market cap of $274.31 million, a price-to-earnings ratio of -2.04 and a beta of 0.46.
Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.09. Poseida Therapeutics had a negative net margin of 190.76% and a negative return on equity of 94.90%. The company had revenue of $25.00 million for the quarter, compared to the consensus estimate of $12.50 million. As a group, analysts predict that Poseida Therapeutics will post -1.77 earnings per share for the current year.
Hedge Funds Weigh In On Poseida Therapeutics
Poseida Therapeutics Company Profile
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.
Recommended Stories
- Five stocks we like better than Poseida Therapeutics
- What is a buyback in stocks? A comprehensive guide for investors
- Meta Stock: 3 Reasons This Stumble Is a Golden Buying Opportunity
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 Staples Stocks to Cushion Lower Consumer Sentiment
- The How And Why of Investing in Oil Stocks
- Zillow’s Earnings Dip: An Opportunity for Visionaries
Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.